Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.

Will support clinical development of Nirsum’s lead development candidate, NRS-033.

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

The acquisition is expected to be completed in the coming days.

Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

Jubilant HollisterStier (JHS) has established itself as a leading player in the contract development and manufacturing ...

Prasinezumab continues to be well tolerated and no new safety signals were observed.

Demonstrates its commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve.

Great Bay Bio (GBB) announced today the first close of its Series B financing round, led by a strategic investment ...

Dr. Marc Damelin possesses extensive industry experience in oncology drug discovery and development across a variety of ...

Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. Established in 2021 and ...